141 related articles for article (PubMed ID: 37122573)
1. Exploring the Impact of COVID-19 Vaccination on Patients Taking Clozapine.
Demler TL; O'Donnell C
Innov Clin Neurosci; 2023; 20(1-3):32-38. PubMed ID: 37122573
[TBL] [Abstract][Full Text] [Related]
2. Outcome of COVID-19 mRNA Vaccination in Patients Treated With Clozapine WHO Previously Went Through SARS-COV-2 Infection.
Moga S; Petric PS; Miron AA; Ifteni P; Teodorescu A
Am J Ther; 2023 May; 30(3):e186-e196. PubMed ID: 37097999
[TBL] [Abstract][Full Text] [Related]
3. Clozapine treatment: Ensuring ongoing monitoring during the COVID-19 pandemic.
Nystazaki M; Alevizopoulos G
Psychiatriki; 2021 Jul; 32(2):165-166. PubMed ID: 33759812
[TBL] [Abstract][Full Text] [Related]
4. [COVID-19 and severe mental illness, especially in clozapine use].
Veerman SRT; Bogers JPAM; Cohen D; Schulte PFJ
Tijdschr Psychiatr; 2021; 63(7):499-508. PubMed ID: 34523699
[TBL] [Abstract][Full Text] [Related]
5. Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System.
Nemani K; Williams SZ; Olfson M; Leckman-Westin E; Finnerty M; Kammer J; Smith TE; Silverman DJ; Lindenmayer JP; Capichioni G; Clelland J; Goff DC
JAMA Netw Open; 2022 May; 5(5):e2210743. PubMed ID: 35522282
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. The Use of Clozapine in the Serious Mental Illness Patients Enrolled in an Assertive Community Treatment Program.
Yee MR; Espiridon E; Oladunjoye AO; Millsaps U; Harvey N; Vora AH
Cureus; 2021 May; 13(5):e15238. PubMed ID: 34188983
[TBL] [Abstract][Full Text] [Related]
8. A case report: Clozapine-induced leukopenia and neutropenia after mRNA COVID-19 vaccination.
Imai T; Ochiai S; Ishimaru T; Daitoku H; Miyagawa Y; Fukuhara R; Boku S; Takebayashi M
Neuropsychopharmacol Rep; 2022 Jun; 42(2):238-240. PubMed ID: 35166466
[TBL] [Abstract][Full Text] [Related]
9. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.
Shuman MD; Trigoboff E; Demler TL; Opler LA
J Psychiatr Pract; 2014 Jan; 20(1):50-8. PubMed ID: 24419309
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics.
Schwarzinger M; Watson V; Arwidson P; Alla F; Luchini S
Lancet Public Health; 2021 Apr; 6(4):e210-e221. PubMed ID: 33556325
[TBL] [Abstract][Full Text] [Related]
11. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study.
Ko T; Dendle C; Woolley I; Morand E; Antony A
Hum Vaccin Immunother; 2021 Nov; 17(11):4048-4056. PubMed ID: 34357827
[TBL] [Abstract][Full Text] [Related]
12. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
13. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
[TBL] [Abstract][Full Text] [Related]
14. Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
Li LL; Zheng C; La J; Do NV; Monach PA; Strymish JM; Fillmore NR; Branch-Elliman W
Vaccine; 2022 Feb; 40(8):1082-1089. PubMed ID: 35078665
[TBL] [Abstract][Full Text] [Related]
15. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
17. Counseling in maternal-fetal medicine: SARS-CoV-2 infection in pregnancy.
Di Mascio D; Buca D; Berghella V; Khalil A; Rizzo G; Odibo A; Saccone G; Galindo A; Liberati M; D'Antonio F
Ultrasound Obstet Gynecol; 2021 May; 57(5):687-697. PubMed ID: 33724545
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and COVID-19 Vaccination: Effects on blood levels and leukocytes. An observational cohort study.
Veerman SRT; Moscou T; Bogers JPAM; Cohen D; Schulte PFJ
Acta Psychiatr Scand; 2022 Aug; 146(2):168-178. PubMed ID: 35322409
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccine acceptance, hesitancy, and determinants among physicians in a university-based teaching hospital in Thailand.
Sirikalyanpaiboon M; Ousirimaneechai K; Phannajit J; Pitisuttithum P; Jantarabenjakul W; Chaiteerakij R; Paitoonpong L
BMC Infect Dis; 2021 Nov; 21(1):1174. PubMed ID: 34809607
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
